Eris Lifesciences Limited (ERIS.BO)
INR 1379.05
(-0.39%)
INR 1379.05
(-0.39%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 20.09 Billion INR | 20.9% |
| 2022 | 16.61 Billion INR | 25.31% |
| 2021 | 13.26 Billion INR | 11.2% |
| 2020 | 11.92 Billion INR | 12.71% |
| 2019 | 10.58 Billion INR | 9.41% |
| 2018 | 9.67 Billion INR | 16.94% |
| 2017 | 8.27 Billion INR | 10.35% |
| 2016 | 7.49 Billion INR | 25.54% |
| 2015 | 5.97 Billion INR | 9.43% |
| 2014 | 5.45 Billion INR | 7.22% |
| 2013 | 5.08 Billion INR | 29.45% |
| 2012 | 3.93 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 7.38 Billion INR | 2.98% |
| 2024 Q1 | 7.19 Billion INR | 30.64% |
| 2023 Q2 | 5 Billion INR | 8.8% |
| 2023 Q4 | 5.5 Billion INR | 13.95% |
| 2023 FY | 20.09 Billion INR | 20.9% |
| 2023 Q1 | 4.6 Billion INR | 16.0% |
| 2023 Q3 | 4.83 Billion INR | -3.4% |
| 2022 Q4 | 3.96 Billion INR | -5.09% |
| 2022 FY | 16.61 Billion INR | 25.31% |
| 2022 Q3 | 4.17 Billion INR | -8.23% |
| 2022 Q2 | 4.55 Billion INR | 16.14% |
| 2022 Q1 | 3.92 Billion INR | 30.21% |
| 2021 Q1 | 3.43 Billion INR | 25.31% |
| 2021 Q3 | 3.28 Billion INR | -7.15% |
| 2021 FY | 13.26 Billion INR | 11.2% |
| 2021 Q2 | 3.53 Billion INR | 2.82% |
| 2021 Q4 | 3.01 Billion INR | -8.22% |
| 2020 Q4 | 2.74 Billion INR | -10.09% |
| 2020 Q1 | 2.88 Billion INR | 18.03% |
| 2020 Q2 | 3.25 Billion INR | 12.91% |
| 2020 Q3 | 3.05 Billion INR | -6.22% |
| 2020 FY | 11.92 Billion INR | 12.71% |
| 2019 Q3 | 2.61 Billion INR | -6.67% |
| 2019 FY | 10.58 Billion INR | 9.41% |
| 2019 Q4 | 2.44 Billion INR | -6.75% |
| 2019 Q2 | 2.8 Billion INR | 3.15% |
| 2019 Q1 | 2.71 Billion INR | 28.81% |
| 2018 Q3 | 2.48 Billion INR | -4.64% |
| 2018 FY | 9.67 Billion INR | 16.94% |
| 2018 Q4 | 2.11 Billion INR | -15.05% |
| 2018 Q2 | 2.6 Billion INR | 5.46% |
| 2018 Q1 | 2.47 Billion INR | 16.44% |
| 2017 Q4 | 2.12 Billion INR | 2.25% |
| 2017 FY | 8.27 Billion INR | 10.35% |
| 2017 Q1 | 1.85 Billion INR | 16.37% |
| 2017 Q2 | 2.3 Billion INR | 24.54% |
| 2017 Q3 | 2.07 Billion INR | -10.03% |
| 2016 Q3 | 1.84 Billion INR | -7.26% |
| 2016 FY | 7.49 Billion INR | 25.54% |
| 2016 Q4 | 1.59 Billion INR | -13.73% |
| 2016 Q2 | 1.98 Billion INR | 9.04% |
| 2016 Q1 | 1.82 Billion INR | 0.0% |
| 2015 FY | 5.97 Billion INR | 9.43% |
| 2014 FY | 5.45 Billion INR | 7.22% |
| 2013 FY | 5.08 Billion INR | 29.45% |
| 2012 FY | 3.93 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bajaj HealthCare Limited | 4.73 Billion INR | -324.391% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 12.004% |
| Hester Biosciences Limited | 3.04 Billion INR | -559.717% |
| Lupin Limited | 200.1 Billion INR | 89.96% |
| Medicamen Biotech Limited | 1.79 Billion INR | -1020.509% |
| Medico Remedies Limited | 1.44 Billion INR | -1286.374% |
| NATCO Pharma Limited | 40.02 Billion INR | 49.797% |
| Achyut Healthcare Limited | 61.36 Million INR | -32638.728% |
| Ajanta Pharma Limited | 42.08 Billion INR | 52.262% |
| Alkem Laboratories Limited | 126.67 Billion INR | 84.139% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1747.675% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 67.128% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -55.083% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 93.001% |
| Brooks Laboratories Limited | 794.86 Million INR | -2427.666% |
| Divi's Laboratories Limited | 78.45 Billion INR | 74.39% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 92.803% |
| FDC Limited | 19.42 Billion INR | -3.407% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 82.992% |
| Granules India Limited | 45.06 Billion INR | 55.415% |
| Gufic Biosciences Limited | 8.06 Billion INR | -149.068% |
| Indoco Remedies Limited | 17.89 Billion INR | -12.277% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -56.854% |
| Ipca Laboratories Limited | 76.22 Billion INR | 73.642% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -862.685% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -3884.695% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1825.665% |
| Laurus Labs Limited | 50.01 Billion INR | 59.832% |
| Mankind Pharma Limited | 103.34 Billion INR | 80.559% |
| Megasoft Limited | 373.95 Million INR | -5272.715% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -74.517% |
| Piramal Pharma Limited | 81.71 Billion INR | 75.412% |
| RPG Life Sciences Limited | 5.82 Billion INR | -245.184% |
| Sigachi Industries Limited | 3.98 Billion INR | -403.6% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -2559.521% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 95.857% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -91.101% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -675.001% |
| Unichem Laboratories Limited | 16.57 Billion INR | -21.221% |
| Windlas Biotech Limited | 6.3 Billion INR | -218.428% |
| ZIM Laboratories Limited | 3.67 Billion INR | -446.818% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 89.438% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -160.845% |
| Wanbury Limited | 5.75 Billion INR | -249.022% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -376.97% |
| Bal Pharma Limited | 3.39 Billion INR | -492.284% |
| Strides Pharma Science Limited | 40.51 Billion INR | 50.405% |
| Venus Remedies Limited | 5.91 Billion INR | -239.698% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -10.666% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -19.302% |
| Shilpa Medicare Limited | 11.51 Billion INR | -74.465% |
| Aarti Drugs Limited | 25.28 Billion INR | 20.543% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 5.183% |
| Suven Life Sciences Limited | 116.92 Million INR | -17082.589% |
| Ind-Swift Limited | 5.02 Billion INR | -299.855% |
| Valiant Laboratories Limited | 1.82 Billion INR | -1003.578% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 42.335% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -62.238% |
| Themis Medicare Limited | 3.81 Billion INR | -426.283% |
| Hikal Limited | 17.84 Billion INR | -12.582% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 81.056% |
| Sequent Scientific Limited | 13.69 Billion INR | -46.682% |
| Novartis India Limited | 3.35 Billion INR | -499.619% |
| Wockhardt Limited | 27.89 Billion INR | 27.962% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 70.026% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -4918.429% |
| Neuland Laboratories Limited | 15.58 Billion INR | -28.909% |
| Morepen Laboratories Limited | 17.01 Billion INR | -18.053% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -1201.49% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -445.082% |